Chemoprevention of prostate cancer: The prostate cancer prevention trial
โ Scribed by Thompson, Ian M.; Coltman, Charles A.; Crowley, John
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 67 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
โฆ Synopsis
BACKGROUND.
A variety of innovative approaches to the prevention of prostate cancer are now available, including selenium, alpha tocopherol, dietary interventions, and vitamin D. Perhaps the most promising opportunity is based upon considerable evidence that cumulative androgen exposure of the prostate contributes to the age-related risk of prostate cancer. METHODS. The Prostate Cancer Prevention Trial has completed randomization of over 18,000 healthy men to either finasteride or placebo. CONCLUSIONS. While the primary objective of this study is to determine whether finasteride can reduce the period prevalence of prostate cancer over a 7-year period, the biologic and data resources of this study will provide multiple opportunities to better understand this most common cancer in U.S. men.
๐ SIMILAR VOLUMES
Demonstration of malignant cells in blood specimens collected during transurethral resection of the prostate (TURP) has implicated TURP in the dissemination of prostatic cancer. Of 153 patients who underwent radiation therapy for prostate cancer between January 1977 and June 1990 and were retrospect
BACKGROUND. Since prostate cancer (PC) development involves a combination of genetic predisposition and promotional mechanisms, especially the metabolic conversion of testosterone to 5โฃ dihydrotestosterone (DHT) by 5โฃ reductase, how do mechanisms in man relate to prostate-seminal vesicle (P-SV) tumo
Prostate cancer is the most common malignancy among men in Western industrialized countries. The molecular pathogenesis of the disease is poorly known. Over the past 10 years, chromosomal aberrations in prostate cancer have been studied with several techniques, such as loss of heterozygosity (LOH),